Clinical Trials Directory

Trials / Completed

CompletedNCT01708525

Feasibility Study: Heavy Water Tissue Labeling Protocol

Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
2 (actual)
Sponsor
Ulthera, Inc · Industry
Sex
All
Age
30 Years – 65 Years
Healthy volunteers
Accepted

Summary

Enrolled subjects undergo tissue labeling to evaluate the rate of collagen synthesis in tissue treated with the Ulthera® System compared to control tissue.

Detailed description

This study is a prospective, single-center, blinded, non-randomized clinical trial. Two subjects who have chosen to have a surgical facelift procedure and agree to drink heavy water for tissue labeling, will be enrolled. Subjects will consume heavy water and collect saliva specimens over the course of the study period, following a specific heavy water labeling protocol. Two weeks after starting the heavy water protocol, subjects will return to the study site to receive one Ultherapy® treatment to the pre-auricular region on one side of the face. The contra-lateral pre-auricular region will serve as a control. Following Ultherapy® treatment, subjects will continue to follow the heavy water protocol for 4 more weeks. Subjects will then return to the study site to undergo resection of the treated and control tissue for analysis during their planned rhytidectomy procedure. Subjects will send in saliva samples on a weekly basis to allow for confirmation that they are drinking the heavy water.

Conditions

Interventions

TypeNameDescription
DEVICEUlthera® System TreatmentFocused ultrasound energy delivered below the surface of the skin
OTHERHeavy WaterA tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.

Timeline

Start date
2012-08-01
Primary completion
2013-11-01
Completion
2013-11-01
First posted
2012-10-17
Last updated
2017-12-11
Results posted
2014-12-12

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01708525. Inclusion in this directory is not an endorsement.